Category: Latest News
-
Gold Falls to Three-Week Low as Markets Assess Oil Prices and Fed Rate Outlook
Gold prices declined further on Wednesday, reaching their lowest level in more than three weeks as investors assessed higher oil prices, rising government bond yields, a stronger U.S. dollar and expectations for Federal Reserve monetary policy. At 01:52 ET (05:52 GMT), XAU/USD fell 0.4% to $4,311.83 an ounce, while Gold Futures declined 0.9% to $4,358.24.…
-
Oil Prices Rise for Third Session as U.S.-Iran Tensions Keep Supply Risks in Focus
Oil prices moved higher for a third consecutive session on Wednesday, although they reduced earlier gains as investors monitored renewed military exchanges between the United States and Iran and their potential implications for Middle Eastern crude supplies. As of 04:46 ET (08:46 GMT), November Brent crude futures were up 0.2% at $94.87 a barrel, while…
-
U.S. Futures Steady as Investors Monitor Oil Prices, Fed Data and Bond Yields: Dow Jones, S&P, Nasdaq, Wall Street
U.S. stock futures were little changed on Wednesday as investors awaited U.S. economic data and the Federal Reserve’s Beige Book while monitoring developments involving the United States and Iran and further increases in global government bond yields. S&P 500 Futures were flat at 7,637.5 points as of 03:20 ET, while Nasdaq 100 Futures were unchanged…
-
Surging Oil and a Global Bond Sell-Off Drag Wall Street Lower to Start September
Stocks began the new month on the back foot Tuesday, as a fresh spike in oil prices and a worldwide jump in bond yields put pressure on equities. Renewed hostilities in the Strait of Hormuz sent crude above $90 a barrel, reviving inflation worries and reinforcing bets that the Federal Reserve could raise interest rates…
-
Auddia’s Influence Healthcare Signs LOI for First Specialty Hospital in Dallas-Fort Worth
The proposed 24,000-square-foot hospital would give Influence Healthcare its first operating facility and represents an early execution milestone ahead of Auddia’s planned combination with Thramann Holdings to form McCarthy Finney. Key Investor Takeaways Why AUUD Stock Is in Focus Influence Healthcare has taken a significant step toward establishing its first operating hospital by signing an…
-
Rezolve Ai H1 Revenue Jumps Nearly 21-Fold to $130.8 Million as Infrastructure Strategy Expands
Rezolve Ai reaffirmed approximately $360 million of FY2026 revenue guidance after rapid first-half growth, while Google’s adoption of its distributed database technology provides a new reference point for its infrastructure-licensing strategy. Key Investor Takeaways Why RZLV Stock Is in Focus Rezolve Ai delivered a sharp acceleration in first-half revenue, reporting $130.8 million for the six…
-
Kustom Entertainment Agrees to Acquire TFL, Adding $238 Million Revenue Ticketing Business
The definitive acquisition would combine Kustom’s festival and ticketing operations with TFL’s profitable inventory distribution network and proprietary technology, subject to financing and other closing conditions. Key Investor Takeaways Why KUST Stock Is in Focus Kustom Entertainment has entered into a definitive Unit Purchase Agreement to acquire all outstanding equity interests in TFL, positioning the…
-
Elbit Systems Wins $270 Million ISR and Targeting Payload Contracts
The six-year contracts add long-duration international demand for Elbit Systems’ SPECTRO and AMPS NG technologies as the company executes against a $32 billion order backlog. Key Investor Takeaways Why ESLT Stock Is in Focus Elbit Systems has secured approximately $270 million of contracts from an international customer covering advanced intelligence, surveillance, reconnaissance and targeting payloads.…
-
Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform
The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion according to the company. Key Investor Takeaways Why VRTX Stock Is in Focus Vertex Pharmaceuticals has completed its acquisition of Crinetics Pharmaceuticals, closing a transaction valued at approximately $10 billion…
-
Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership
The proposed exclusive U.S. distribution agreement would give Kala a commercial opportunity in its established ophthalmology market while leaving Virotek responsible for laboratory operations and clinical reporting. Key Investor Takeaways Why KALA Stock Is in Focus Kala Bio has entered into a letter of intent with Virotek outlining a proposed exclusive U.S. distribution partnership for…